Bachem Renews Supply Agreement with AstraZeneca

Date Posted: Thursday, June 21, 2007

Print Email to a friend

Bachem has announced the renewal of a supply agreement with AstraZeneca, thereby extending the existing agreement between these two companies.

Bachem has supplied AstraZeneca for more than 15 years with goserelin, the active substance of Zoladex, which represents one of AstraZeneca’s medicines in oncology. Goserelin, a peptide active ingredient, has been one of the best-selling products of the Bachem Group for many years.

Dr. Rolf Nyfeler, CEO of the Bachem Group, commented that "The renewed extension of the agreement is an enormous vote of confidence in Bachem. It not only means the continued safeguarding of sales for goserelin, but also confirms that our focus on quality, service and delivery reliability is the foundation for our many years of successful collaboration with customers, however large they may be."

The scope of the new agreement is comparable to that of the previous agreement and runs for a further period of five years. Based on the proven partnership, Bachem will be even more closely integrated in AstraZeneca’s supply chain management and will provide additional logistics and quality control services.

Further Information: